The June 2026 protocol tests oral probiotics plus a topical secretome, the cell-derived mixture under study, as add-ons to standard acne therapy. For people with acne-prone skin, it is an 8-week test plan, not proof of benefit, with long-term safety and relapse still open. According to BMJ Open, the phase 2 double-blind randomized protocol uses four parallel arms the June 2026 protocol. The plan runs 8 weeks with pretest and posttest checks of acne severity, faecal microbiome restoration and clinical outcomes.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the 8-week protocol will measure
- What probiotic results show so far
- Why secretome products need caution
- What to do if you have acne-prone skin
What the 8-week protocol will measure
The trial compares standard acne therapy alone against standard therapy plus an oral probiotic, plus a topical secretome, or plus both. Each group receives the same severity and microbiome checks before and after treatment.
The short window suits a phase 2 signal check. It can show early change in lesions, tolerance and microbiome markers. It cannot show lasting clearance, relapse rate or rare harms.
What probiotic results show so far
According to the Medicina systematic review, pooled data from three double-blind trials with 231 participants showed a modest drop in inflammatory severity the December 2025 review. The authors rated the base as small, mixed and low-to-moderate certainty.
One 12-week double-blind trial in ages 12-30 tested Lacticaseibacillus rhamnosus CECT 30031 plus Arthrospira. Acne Global Severity Scale improvement occurred in 50% on active treatment versus 29.4% on placebo, according to the PubMed trial record the 12-week trial record. The result is encouraging but narrow and strain-specific.
Why secretome products need caution
Secretome and exosome skin products sit in a strict regulatory space in the United States. According to Dermatological Reviews, products meant to affect tissue function face drug or biologic rules and need premarket approval the 2026 Dermatological Reviews summary. The same source reports that no exosome product has completed FDA approval to date.
That gap matters for shoppers. A cosmetic label does not prove drug-level safety, strength or acne benefit. Trial-grade secretome is not the same as an over-the-counter serum.
What to do if you have acne-prone skin
Stay on treatment with proven benefit while this research runs. Use the trial as context for questions, not as a reason to stop a retinoid, benzoyl peroxide or prescribed therapy.
According to Medicina, small prior trials and short follow-up cannot assess long-term safety or relapse. Continue proven therapy and discuss any probiotic or secretome add-on with a dermatologist.
- Keep your current routine stable and track breakouts, irritation and missed doses
- Bring a full product and supplement list to your visit
- Ask whether a specific probiotic strain, dose and duration fits your case
- Ask about risks, drug interactions, cost and what success would look like in 8-12 weeks
- Do not add an exosome or secretome product sold for tissue repair without medical input
You Might Also Like
- Skin Microbiome Outcomes in the 2026 Probiotic Acne Review: Evidence Limits and Open Questions for People With Acne-Prone Skin
- Probiotics for Acne in a 2026 Systematic Review and Meta-Analysis: Evidence Limits and Open Questions for People With Acne-Prone Skin
- The 2026 Global Delphi Consensus on Acne and the Microbiome: Evidence Limits and Open Questions for People With Acne-Prone Skin